Latest news
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks - finance.yahoo.comfinance.yahoo.com · Sun, 09 Aug 2026 00:19:00 GMTHalozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales - finance.yahoo.comfinance.yahoo.com · Thu, 06 Aug 2026 20:45:43 GMT